Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2019

01-08-2019 | Metastasis | Review

De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis

Authors: Arif Ali Awan, Brian Hutton, John Hilton, Sasha Mazzarello, Catherine Van Poznak, Lisa Vandermeer, Brianne Bota, Carol Stober, Marta Sienkiewicz, Dean Fergusson, Risa Shorr, Mark Clemons

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Login to get access

Abstract

Purpose

Bone-modifying agents (BMAs) such as bisphosphonates and denosumab are usually administered every 4 weeks (standard) in patients with bone metastases from breast cancer to prevent skeletal-related events (SREs). Recent randomized controlled trials suggest every 12-week (de-escalated) dosing interval may be non-inferior. The objective of this systematic review and meta-analysis was to compare the efficacy and harms of standard with de-escalated administration of BMA’s in patients with bone metastases from breast cancer.

Methods

We searched Medline, PubMed, and the Cochrane Register of Controlled Trials from 1947 to March 14, 2018 and conference abstracts from (2014–March 14, 2018) for randomized clinical trials comparing every 4-week and every 12-week dosing interval of bone-modifying agents. Using PRISMA guidelines, meta-analyses were performed using random-effects models, with findings reported as risk ratios with 95% confidence intervals (CI).

Results

From a total of 1311 citations, we identified 8 full-text articles and 1 abstract comprising data from 5 completed randomized clinical trials (n = 1807). Zoledronate administration every 12 weeks compared to every 4 weeks produced a summary risk ratio of 1.05 (95% CI 0.88–1.25) for patients with ≥ 1 on-study SRE indicating similar efficacy. These results did not differ whether patients had received prior intravenous bisphosphonate. De-escalation was associated with a non-statistically significant lower risk of increased creatinine (summary risk ratio 0.41 [95% CI 0.15–1.16]). Currently, there are insufficient data for pamidronate and denosumab de-escalation.

Conclusions

These data are supportive of de-escalation of zoledronate from onset for patients with bone metastases from breast cancer.
Appendix
Available only for authorised users
Literature
1.
Coleman RE (1997) Skeletal complications of malignancy. Cancer-Am Cancer Soc 80(8 Suppl):1588–1594
2.
Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55(1):61–66CrossRef
3.
Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115(2):423–428CrossRef
4.
Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27(3):165–176CrossRef
5.
Richards MA, Braysher S, Gregory WM, Rubens RD (1993) Advanced breast cancer: use of resources and cost implications. Br J Cancer 67(4):856–860CrossRef
6.
Body JJ, Chevalier P, Gunther O, Hechmati G, Lamotte M (2013) The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium. J Med Econ 16(4):539–546CrossRef
7.
Clemons M, Gelmon KA, Pritchard KI, Paterson AHG (2012) Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol 19(5):259–268CrossRef
8.
Holen I, Coleman RE (2010) Bisphosphonates as treatment of bone metastases. Curr Pharm Des 16(11):1262–1271CrossRef
9.
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377–387PubMed
10.
Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES et al (2017) Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol 35:3978CrossRef
11.
Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL et al (2011) American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29(9):1221–1227CrossRef
12.
Network NCC: Breast Cancer Version 1.2018 (April 23, 2018) (2018)
13.
Hutton B, Addison C, Mazzarello S, Joy AA, Bouganim N, Fergusson D, Clemons M (2013) De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—a survey of Canadian oncologists. J Bone Oncol 2(2):77–83CrossRef
14.
Van Poznak CH, Von Roenn JH, Temin S (2011) American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract 7(2):117–121CrossRef
15.
Verma S, Kerr-Cresswell D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, Cesta AM, Clemons M (2004) Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists. Support Care Cancer 12(12):852–858CrossRef
16.
Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R et al (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14(7):663–670CrossRef
17.
Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O’Connor T et al (2017) Effect of longer-interval versus standard dosing of zoledronic acid on skeletal events in patients with bone metastases A randomized clinical trial. Jama-J Am Med Assoc 317(1):48–58CrossRef
18.
Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M et al (2017) Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. Jama Oncol 3:906CrossRef
19.
Fernandes R, Siegel P, Komarova S, Hilton J, Addison C, Ibrahim MFK, Werier J, Dennis K, Singh G, Amir E et al (2016) Future directions for bone metastasis research—highlights from the 2015 bone and the Oncologist new updates conference (BONUS). J Bone Oncol 5(2):57–62CrossRef
20.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Grp P-P: preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Br Med J 2015:349
21.
Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Br Med J 343:d5928CrossRef
22.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, Grp GW (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 336(7650):924–926CrossRef
23.
Schünemann H BJ, Guyatt G, Oxman A (eds) (2013) GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group, 2013
24.
McMaster University dbEP, Inc. (2015) GRADEpro GDT: GRADEpro guideline development tool [Software]
25.
Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558CrossRef
26.
The Nordic Cochrane Centre TCC (2014) Copenhagen: review manager (RevMan) [Computer program]. Version 5.3
27.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj 339:b2535CrossRef
28.
Addison CL, Pond GR, Zhao HJ, Mazzarello S, Vandermeer L, Goldstein R, Amir E, Clemons M (2014) Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. Springerplus 3:577CrossRef
29.
Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M (2013) Randomized feasibility study of de-escalated (every 12 week) versus standard (every 3 to 4 week) intravenous pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol-Cancer 36(5):436–442CrossRef
30.
Coleman RE, Wright J, Houston S, Agrawal R, Purohit OPK, Hayward L, Simmonds P, Waterhouse A, Marshall H, Investigators B (2012) Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer. J Clin Oncol 30(15):511
31.
Kuchuk I, Beaumont JL, Clemons M, Amir E, Addison CL, Cella D (2013) Effects of de-escalated bisphosphonate therapy on the functional assessment of cancer therapy-bone pain, brief pain inventory and bone biomarkers. J Bone Oncol 2(4):154–157CrossRef
32.
Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS et al (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25(28):4431–4437CrossRef
33.
Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS et al (2008) Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 14(20):6690–6696CrossRef
34.
Templeton AJ, Stalder L, Bernhard J, Brauchli P, Gillessen S, Hayoz S, KlIngblel D, Matter-Walstra K, Thurlimann BJK, Von Moos R (2014) Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: a noninferiority phase III trial (SA 96/12, REDUSE). J Clin Oncol 32(15):20
35.
Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27(10):1564–1571CrossRef
36.
National Cancer Institute PROCSG (2006) Common Terminology Criteria for Adverse Events (CTCAE) v3.0
37.
Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H et al (2015) Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol 26(2):368–374CrossRef
38.
Ibrahim MFK, Clemons MJ, Hutton B, Hilton JF, Vandermeer L, Mazzarello S, Shorr R (2015) Should de-escalation of bone-targeted agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. J Clin Oncol 26:2205
39.
Cao L, Yang YJ, Diao JD, Zhang XH, Liu YL, Wang BY, Li ZW, Liu SX (2017) Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis. Oncotarget 8(52):90308–90314PubMedPubMedCentral
40.
Yanae M, Fujimoto S, Tane K, Tanioka M, Fujiwara K, Tsubaki M, Yamazoe Y, Morishima Y, Chiba Y, Takao S et al (2017) Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid. J Bone Oncol 8:18–22CrossRef
41.
Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ (2017) Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (alliance). J Clin Oncol 35:3949CrossRef
42.
Clemons M (2016) A pragmatic randomised, multicentre trial comparing 4-weekly versus 12-weekly administration of bone-targeted agents in patients with bone metastases from either castration-resistant prostate cancer or breast cancer—the REaCT-BTA Study. Clinicaltrialsgov NCT02721433
Metadata
Title
De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis
Authors
Arif Ali Awan
Brian Hutton
John Hilton
Sasha Mazzarello
Catherine Van Poznak
Lisa Vandermeer
Brianne Bota
Carol Stober
Marta Sienkiewicz
Dean Fergusson
Risa Shorr
Mark Clemons
Publication date
01-08-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05265-1

Other articles of this Issue 3/2019

Breast Cancer Research and Treatment 3/2019 Go to the issue

Epidemiology

Adult weight gain accelerates the onset of breast cancer

Epidemiology

Breast cancer risk in relation to plasma metabolites among Hispanic and African American women

Review

Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis

Letter to the Editor

HER2+ and triple-negative phenotypes in invasive lobular carcinoma might have different specific biological features

Preclinical study

T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer

Clinical trial

Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits